NCT00322712终止不适用
INST 0603C Chart Review on Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Time to Death
研究概览
简要总结
Chart Review of patients with pancreatic cancer treated with combination of irinotecan, oxaliplatin and cetuximab.
详细描述
Chart Review to describe the clinical outcomes in patients pancreatic cancer treated with combination of irinotecan, oxaliplatin and cetuximab.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with unresectable/metastatic pancreatic cancer treated in the UNM Cancer Research and Treatment Center.
排除标准
- •Not specified.
结局指标
主要结局
Time to Death
时间窗: From date of treatment until time of death
Length of survival of patients treated with a combination of Oxaliplatin 60mg/m2, Irinotecan 90mg/m2, and Cetuximab 250 mg/m2 delivered every other week.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic CancerOverall SurvivalNCT03726021Qingdao Central Hospital47
进行中（未招募）
不适用
Phase II study of Oxaliplatin / Irinotecan / Cetuximab as first line therapy in locally advanced or metastatic gastric cancerPatients with histologically proven inoperable locally advanced or metastatic gastric cancerEUCTR2006-001989-16-ATAGMT
已完成
不适用
Phase 1 study of irinotecan and cisplatin with concurrent thoracic radiotherapy in patients with limited-disease small cell lung cancer (LD-SCLC).imited-disease small cell lung cancer (LD-SCLC).NL-OMON23572Department of Medical OncologyErasmus University Medical Center / Daniel den Hoed Kliniek3008 AE ROTTERDAM9
Unknown
2 期
Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal CancerColorecal NeoplasmsSecondaryNCT00506571National Cancer Center, Korea42
已完成
2 期
A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric CancerStomach NeoplasmsNCT00512681National Cancer Center, Korea44